Dapagliflozin reduces hospitalization risk in adults with chronic kidney disease - Healio

The SGLT2 inhibitor dapagliflozin was associated with a reduced hazard for hospitalization owed to immoderate origin successful patients with chronic kidney illness with and without benignant 2 diabetes, according to a station hoc investigation of the DAPA-CKD trial.

Previous information from the randomized, double-blind, placebo-controlled, signifier 3 DAPA-CKD proceedings revealed an “overwhelming benefit” of dapagliflozin successful adults with chronic kidney illness (CKD), according to the manufacturer, AstraZeneca. The attraction was shown to trim worsening renal relation oregon renal decease compared with placebo, careless of patients’ diabetes status.

Data derived from: Schechter M, et al. Ann Intern Med. 2022;doi:10.7326/M22-2115.

“Although cardiovascular and kidney outcomes with SGLT2 inhibitors person been studied extensively, determination is simply a paucity of information evaluating the effects of SGLT2 inhibitors connected hospitalizations for immoderate cause,” Meir Schechter, MD, PhD, a post-doc chap astatine the Diabetes Clinical Research Center astatine Hadassah Medical Center successful Israel, and colleagues wrote successful Annals of Internal Medicine.

For the existent analysis, Schechter and colleagues examined information from 4,304 patients (mean age, 61.8 years; 33.1% women) with CKD to analyse the effects of dapagliflozin (10 mg erstwhile daily) vs. placebo connected archetypal and consequent hospitalizations.

Among the 2,906 participants with benignant 2 diabetes, 1,455 received dapagliflozin and 1,451 received placebo. Of those without benignant 2 diabetes, 697 received dapagliflozin and 701 received placebo.

Over a median follow-up play of 2.4 years, Schechter and colleagues identified 2,072 hospitalizations among 1,224 (28.4%) participants.

Dapagliflozin was associated with a little hazard for archetypal hospitalization (HR = 0.84; 95% CI, 0.75-0.94) and each hospitalizations (rate ratio [RR] = 0.79; 95% CI, 0.7-0.89) compared with placebo, according to the researchers. At slightest 1 hospitalization was reported successful 26.3% of patients successful the dapagliflozin group, yielding an lawsuit complaint of 143.7 per 1,000 person-years, and 30.6% of patients successful the placebo group, for an lawsuit complaint of 171.9 events per 1,000 person-years.

Schechter and colleagues further reported that, compared with placebo, dapagliflozin reduced the hazard for hospitalizations owed to cardiac disorders (RR = 0.67; 95% CI, 0.53-0.86), renal and urinary disorders (RR = 0.61; 95% CI, 0.46-0.79), metabolism and nutrition disorders (RR = 0.61; 95% CI, 0.41-0.91) and neoplasms (RR = 0.62; 95% CI, 0.39-0.96).

“There was nary grounds that the effects of dapagliflozin connected archetypal and each hospitalizations varied by baseline beingness of benignant 2 diabetes,” they wrote.

Since the survey was conducted arsenic a station hoc analysis, Schechter and colleagues noted that it “should beryllium viewed arsenic hypothesis-generating.” Still, the researchers said the findings person “major objective relevance,” arsenic hospitalizations lend to CKD load and trim health-related prime of beingness among patients.

“These findings item further benefits of dapagliflozin beyond those seen for cardiovascular and kidney events, all-cause and cause-specific mortality, eGFR slope and albuminuria and should beryllium considered erstwhile evaluating the totality of grounds favoring proviso of dapagliflozin to patients with CKD,” they wrote.